Biomarin’s effort to block Yuviwel, Ascendis’ TransCon CNP drug, has reached a lull.  Last year, Biomarin brought a proceeding before the International Trade Commission (ITC) to block Ascendis from importing its drug.  The ITC held an evidentiary hearing in late April of this year, and the ALJ is scheduled to issue its “final initial” determination by the end of August.  In the meantime, the Commission Investigative Staff (Staff) filed its brief following the evidentiary hearing.  Does the Staff’s findings bode well or ill for Ascendis’ hopes of keeping its Yuviwel drug on the market?